

Hillary Scholten is endorsed by San Francisco liberal Nancy Pelosi, has taken thousands of dollars from her, and supports Pelosi's extreme agenda in Congress.

BACKUP:

Hillary Scholten has been endorsed by San Francisco liberal Nancy Pelosi and has taken thousands of dollars from her:

- In July 2022, Nancy Pelosi tweeted a photo collage of Democratic candidates to support, which included Hillary Scholten. "We won't let insurrectionists and extreme Supreme Court decisions destroy our Democracy as we know it. We will fight back! Our plan: don't agonize, organize. #DefendOurDemocracy. Hold the House. Support our competitive House Democratic Frontliners and Challengers. Let's go! -NP" (Nancy Pelosi, [Twitter](#), 7/1/22)

Editor's Note: Scholten's photo is in the fourth row from top, fourth photo from the left.



(Nancy Pelosi, [Twitter](#), 7/1/22)

- Nancy Pelosi also endorsed Hillary Scholten's 2020 congressional campaign. ".@HillaryScholten is committed to being a strong voice for #MI03 on key local issues that are impacted by national policy – from housing to immigration to clean running water #ForThePeople of West Michigan." (Nancy Pelosi, [Twitter](#), 6/29/20)



(Nancy Pelosi, [Twitter](#), 6/29/20)

- Nancy Pelosi is “very, very proud” to be called a “San Francisco liberal.” “An exuberantly confident House Minority Leader Nancy Pelosi (D-CA) said on Tuesday evening that Democrats will take back the House of Representatives next week and told CBS’s Stephen Colbert that she is ‘very, very proud’ to be called a ‘San Francisco liberal.’” (Tony Lee, “Pelosi Guarantees Midterm Win, ‘Very, Very Proud’ to Be ‘San Francisco Liberal,’” [Breitbart](#), 10/31/18)
- Hillary Scholten has received \$28,000 from Nancy Pelosi’s campaign account and from her leadership PAC. (Federal Election Commission, [Itemized Receipts](#), Accessed: 8/14/22)

Editor’s Note: PAC to the Future [is Nancy Pelosi’s](#) leadership PAC.

Contributions to Hillary Scholten from Nancy Pelosi			
Source Name	Recipient	Receipt Date	Amount
Nancy Pelosi For Congress	Scholten For Congress	05/24/2022	\$2,000.00
PAC To The Future	Scholten For Congress	05/24/2022	\$5,000.00
Nancy Pelosi For Congress	Scholten For Congress	03/28/2022	\$2,000.00
PAC To The Future	Scholten For Congress	03/28/2022	\$5,000.00
PAC To The Future	Scholten For Congress	08/10/2020	\$5,000.00
Nancy Pelosi For Congress	Scholten For Congress	08/10/2020	\$2,000.00
Nancy Pelosi For Congress	Scholten For Congress	06/29/2020	\$2,000.00
PAC To The Future	Scholten For Congress	06/29/2020	\$5,000.00
			TOTAL: \$28,000

(Federal Election Commission, [Itemized Receipts](#), Accessed: 8/14/22)

Hillary Scholten supports key elements of Nancy Pelosi’s extreme agenda in Congress, including H.R. 1 – legislation to overhaul elections and campaign finance – and H.R. 3, legislation to give the federal government authority to control prescription drug prices:

- **Nancy Pelosi’s policy agenda includes H.R. 1, a measure to overhaul campaign finance and elections.** “Speaker Nancy Pelosi said Monday she would press ahead early next year with a campaign finance and elections overhaul, even as the measure may face the same Senate fate it did this Congress: doom. House Democrats passed their signature overhaul measure in March 2019 and dubbed it HR 1, indicating its priority. Senate Majority Leader Mitch McConnell blocked it in his chamber, however.” (Kate Ackley, “Pelosi, Democrats renew push to overhaul election, campaign finance laws,” [Roll Call](#), 11/6/20)
- **In September 2020, End Citizens United endorsed Hillary Scholten for Congress, noting that Scholten supports H.R. 1, the For the People Act.** “Scholten supports critical reform legislation like the For the People Act (H.R. 1) End Citizens United (ECU) and Let America Vote (LAV) today endorsed Hillary Scholten in Michigan’s Third Congressional District. Hillary supports key reform legislation like the For the People Act, the most sweeping anti-corruption, voting rights and ethics reform bill since Watergate, and the DISCLOSE Act.” (End Citizens United, “End Citizens United and Let America Vote Endorse Hillary Scholten in MI-03,” [Press Release](#), 9/25/20)
 - **Hillary Scholten has voiced her strong support for publicly funded elections.** “First and foremost I’m gonna fight like hell for campaign finance reform and make sure that we can have publicly funded elections.” (Scholten for Congress Rooftop Meet and Greet, [clipped](#), 8/12/2020)
- **Nancy Pelosi crafted H.R. 3, the Lower Drug Costs Now Act.** “House Speaker Nancy Pelosi visited Seattle’s Harborview Medical Center Tuesday morning to talk about lowering prescription drug costs. Last month Pelosi unveiled her plan, the ‘Lower Drug Costs Now Act.’ This would make lower prices negotiated by Medicare available to all Americans, require drugmakers to pay rebates if their prices go above the inflation rate, and put a limit of \$2,000 on co-pays for seniors.” (Kierra Elfalan, “Pelosi Pushes For Lowered Prescription Drug Costs During Seattle Visit,” [ABCSeattle](#), 10/8/19)
- **In December 2019, Hillary Scholten criticized Justin Amash for voting against H.R. 3.** “This week @justinamash voted against bi-partisan efforts to: *hold drug companies accountable and lower the cost of presc. drugs (HR3) *help farmers in MI-03 with workforce modernization (HR5038) *protect the Great Lakes and combat the effects of climate change (HR729) #onnotice” (Hillary Scholten, [Twitter](#), 12/15/2019)



(Hillary Scholten, [Twitter](#), 12/15/2019)

- H.R. 3 would allow the federal government to negotiate drug prices and cap drug costs.** “Passage of the bill, as amended, that would allow the Health and Human Services Department to negotiate prices for certain drugs under Medicare programs and would make a number of modifications to Medicare programs related to drug costs and plan benefits. Specifically, the bill would establish a fair price negotiation program in which HHS would enter into agreements with drug manufacturers to negotiate maximum fair prices for certain drugs. It would allow the department to negotiate a ‘maximum fair price’ for insulin and up to 250 other Medicare-eligible, brand-name drugs that do not have generic competition, including 125 drugs that account for the greatest national spending and 125 drugs that account for the greatest spending under Medicare parts C and D. The bill would require the department to negotiate the maximum price of at least 25 drugs for 2023 and at least 50 drugs in each subsequent year. It would require that such maximum prices would not exceed 120% of a drug's average international price or 85% of the average manufacturer price for drugs for a year. The bill would subject drug manufacturers who do not reach a negotiated agreement for a drug to excise taxes based on gross sales of that drug. It would require manufacturers to offer negotiated prices to private health insurers. The bill would also make adjustments to payments, pricing structures, and programs related to Medicare parts B and D. Among other provisions, it would place a \$2,000 annual out-of-pocket cap on costs for Medicare Part D beneficiaries, expand eligibility for a Part D low-income subsidy program, and add comprehensive vision, dental, and hearing coverage under Medicare Part B. Finally, it would authorize funding for HHS programs to address opioid and substance use disorders and authorize funding for National Institutes of Health and Food and Drug Administration activities related to the development of new drugs and medical treatments.” (CQ, “[House Vote 682 - HR 3: Drug Price Negotiations - Passage](#),” 12/12/19)
- H.R. 3 would give the federal government the authority to fine companies that refuse to participate.** “In a letter to fellow Democrats, the lawmaker from Maryland said the Lower

Drug Costs Now Act will be under considerations by several House panels when Congress returns to session next week. ‘And it is possible that we will consider it on the floor the week of Oct. 28,’ Hoyer said. The measure would give the federal government the authority to directly negotiate prescription drug prices and would fine companies that refuse to participate. (Susan Ferrechio, “House May Vote On Prescription Drug Bill This Month,” [The Washington Examiner](#), 10/11/19)

- **The Heritage Foundation called the bill “an unprecedented exercise of raw government power.”** “The bill represents an unprecedented exercise of raw government power. The federal government already imposes price curbs across a range of programs, requiring manufacturers to pay the government rebates in Medicaid and the ‘340B’ program, and discounts in Medicare, as well as to make various price concessions in the Veterans Affairs health system. These provisions all are confined to federal programs, but nonetheless have distorted drug prices throughout the health sector.” (Doug Badger, “Why Pelosi’s Drug Price Control Scheme Would Be A Poison Pill To Innovation And Access,” [The Heritage Foundation](#), 9/24/19)